Summary The understanding of the pathophysiology and the monitoring of metastatic bone disease remains unsatisfactory. We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate. We studied 19 ambulatory patients-with advanced breast cancer and extensive bone metastases who did not receive any systemic antineoplastic therapy. Pamidronate was administered at doses of 30, 60, 90 or 120 mg and the patients were followed weekly during a mean of 8 (range 4-10) weeks. Compared with healthy premenopausal women, the percentage of elevated values at baseline was 47% for fasting urinary calcium (uCa), 74% for hydroxyproline, 83% for CrossLaps (a new marker of type collagen degradation) and 100% for the collagen cross-links (measured by high performance liquid chromatography), namely pyridinoline (Pyr) and deoxyPyr (D-Pyr). Pretreatment levels of uCa did not correlate significantly with any of the four markers of bone matrix resorption, whereas the correlations between these four markers were generally significant (rs=0.43-0.71). Alkaline phosphatase correlated significantly with markers of bone matrix resorption (rs=0.54-0.74). All parameters, except phosphaturia (uPi) and the bone formation markers (osteocalcin and alkaline phosphatase), fell significantly after pamidronate therapy, up to day 42 for hydroxyproline, D-Pyr and CrossLaps and day 56 for uCa. This longer lasting effect was probably due to the parathyroid hormone (PTH) surge following the decrease in serum calcium, implying that the decrease in uCa can overestimate the effects of bisphophonates on bone resorption. The decrease in bone turnover parameters was most marked for CrossLaps, indicating the potential of this new marker for monitoring therapy. Sequential determinations of markers of bone matrix resorption should be useful in delineating the optimal therapeutic schemes of bisphosphonates and for evaluating treatment effects on bone in cancer patients.
The monitoring of metastatic bone disease remains a daily challenge for the practising oncologist. Metastatic tumour cells in the skeleton markedly stimulate osteoclast-mediated bone resorption, and biochemical parameters of bone resorption could be useful for a sensitive and specific assessment of the extent of tumourinduced osteolysis (TIO) (Body, 1992) . The fasting urinary excretions of calcium (uCa) and of hydroxyproline constitute the classical and widely available parameters of bone resorption in cancer patients (Niell et al, 1983; Body et al, 1987; Body, 1992) . In patients receiving systemic treatment for bone metastases from breast cancer, Coleman et al have shown a decrease in uCa 1 month after systemic therapy in those patients subsequently shown to be 'partial responders' by classical UICC criteria. The same patients also had a transient increase in the levels of bone formation markers (Coleman et al, 1988) . Several new markers of bone turnover have recently been introduced that are claimed to be more sensitive and more specific for assessing bone turnover than uCa or hydroxyproline, and the clinician is now faced with an impressive choice of markers (Delmas, 1990 ). The intermolecular cross-linking compounds of collagen could be particularly well suited to the diagnosis and monitoring of the breakdown of bone matrix by cancer cells because of their high specificity for bone, particularly deoxypyridinoline (Delmas et al, 1991 ; Uebelhart et al, 1991) ; however, their evaluation in cancer patients is still quite limited (Lipton et al, 1993) .
On the other hand, bisphosphonates have become the standard treatment of tumour-induced hypercalcaemia (TIH) (Body et al, 1987; Body, 1992; Ralston, 1992) , and they are increasingly used for the treatment of bone metastases as the essential pathogenic role of osteoclasts in tumour-induced osteolysis (TIO) is now well demonstrated (Averbuch, 1993; Body, 1993) . Optimum therapeutic schemes remain, however, largely unknown (Averbuch, 1993; Body, 1993) , and the use of biochemical parameters of bone turnover could be quite useful in the determination of such schemes. Moreover, biochemical markers could help provide a better understanding of the pathophysiology of TIO, notably the possible uncoupling between bone formation and bone resorption (Body, 1992) .
We have compared several markers of bone turnover in 19 patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate to better delineate the relative interest of newly developed markers of bone resorption compared with the routinely used uCa. We studied 19 post-menopausal patients suffering from advanced breast cancer and extensive metastatic bone involvement who were no longer eligible for standard antineoplastic treatments. The presence of bone metastases was demonstrated by scintigraphy and radiography, and by CT scan when necessary. The extent of bone metastatic involvement was estimated by counting on radiographs the number of bones involved; we counted only one site when the invaded bones were adjacent (e.g. vertebrae). The median number of invaded skeletal sites was four (range 2-8). We estimated the influence of the extent of bone metastatic involvement on the levels of biochemical parameters by separating the patients into three groups, i.e. patients with 2-3, 4-6 or > 6 invaded bones. The patients did not receive any other systemic antineoplastic therapy or any drug known to influence bone or calcium metabolism during the study period. All subjects were ambulatory female patients suffering from advanced metastatic breast cancer, with a median age of 60 (range 40-78) years. This study was part of a trial protocol examining the dose-response effects of pamidronate in patients with TIO that had been approved by the Ethics Committee of Institut J Bordet. All patients were normocalcaemic, and they were recruited and treated consecutively by the following doses of pamidronate (Aredia, Ciba-Geigy, Basle, Switzerland): 30 mg for the first four patients, then 60 mg
Laboratory determinations
Blood measurements included serum calcium (normal values, Nl 2.12-2.57 mmol 1-'), inorganic phosphate (Pi, Nl 0.71-1.45 mmol 1-'), intact PTH (Incstar assay, Nl 10-50 pg ml-'), alkaline phosphatase (Alk Phos, Nl <110 mU ml-') and osteocalcin (BGP, Incstar assay; Nl 0.8-5.7 ng ml-') Dumon and Body, 1995) . Because of the pathological increase in bone resorption after the menopause (Delmas, 1990; Delmas et al, 1991; Uebelhart et al, 1991) , parameters of bone resorption were compared with values measured in pre-as well as in postmenopausal untreated healthy women. Urinary measurements (2-h morming-fasting specimens) included uCa (Nl <0.45 or <0.59 mmol per mmol of creatinine in pre-and post-menopausal women respectively), uPi, hydroxyproline (NI <37 or <40 ,umol per mmol of creatinine), pyridinoline (Pyr, Nl <47 or <78 nmol per mmol of creatinine) and deoxyPyr (D-Pyr, NI <7.3 or <12.0 nmol per mmol of creatinine) (Delmas, 1990; Delmas et al, 1991; Uebelhart et al, 1991; Body and Delmas, 1992; Body et al, 1995) . Crosslinks were measured by fluorometry after extraction, cellulose chromatography and high-performance liquid chromatography (HPLC) (Uebelhart et al, 1990 ).
British Journal of Cancer (1997) We also measured CrossLaps excretion before therapy and at days 7, 21, 42, 56 and 70 after pamidronate. The CrossLaps assay (Osteometer, Denmark) estimates the level of type I collagen degradation using an ELISA based on an eight amino acid peptide sequence specific to the C-telopeptide a, chain of collagen; this sequence contains an important region for the intermolecular cross-links (Bonde et al, 1994) (Nl <408 or <780 ,ug mmol-' creatinin in pre-and post-menopausal women respectively).
Statistical analysis
We used classical statistical tests (non-parametric correlations (rs) and t-tests) with the Statistica program version 4 (Statsoft, Tulsa, OK, USA). An analysis of covariance (ANCOVA, with mean pretreatment determinations as the co-variable) was performed to compare the changes in the different markers after therapy. We also used non-parametric confidence intervals to estimate the duration of the effects of bisphosphonate therapy.
RESULTS

Baseline values
The mean values of the evaluated markers of bone resorption (uCa, hydroxyproline, Pyr, D-Pyr, CrossLaps) are shown in Figure 1 (Gamero et al, 1994) . Nevertheless, it remains to be proven that such new markers of bone resorption have a higher diagnostic yield for bone metastases than the classical hydroxyproline assay as in our study, the sensitivity of the CrossLaps assay was not superior to the one of hydroxyproline. However, the impressive changes in this newer marker after therapy with bisphosphonates suggest that it could be especially useful in the monitoring of treatment effects on bone turnover. The decrease in CrossLaps excretion 1 week after pamidronate was indeed quite striking, and it would be worthwhile to monitor changes in such markers after antineoplastic therapy to 60 80 determine if they can detect the future responders earlier than with conventional scintigraphic or radiological means. This is especially worthwhile to investigate that this marker can be easily fter pamidronate measured, unlike crosslinks excretion whose measurement is the matrix (D-Pyr, quite sophisticated (Delmas et al, 1991; Uebelhart et al, 1991) .
n r a (ua, P ) , are Hydroxyproline, D-Pyr and CrossLaps all remained significantly 'n again in B for lower than baseline up to day 42. After bisphosphonate therapy, the urinary excretion of calcium appears to be an unreliable marker in the monitoring of bone resorption during therapy, as it is further decreased by the PTH surge following the decrease in hydroxyproline serum calcium and could thus overestimate the duration of the effects of bisphosphonates on bone resorption. The superiority of the markers of bone matrix resorption compared with uCa in the monitoring of osteolysis should, however, be confirmed in longer term studies. The absence of significant changes in phosphaturia haturia (uPi), fell was probably owing to contrasting effects, namely the decrease in ite therapy. The filtered load, itself due to the inhibition of bone resorption, in -oncentrations of opposition with the phosphaturic effect of PTH. rent (P<0.0001, Markers of bone matrix resorption correlated well with each ). They were no other, whether before or after pamidronate administration. We 3 for uCa (90% chose to focus on the correlations with D-Pyr because of the wellhydroxyproline demonstrated specificity of this marker for assessing resorption of Lys), day 56 for bone collagen (Delmas, 1990; Delmas et al, 1991) . The complete r (14-28 days). lack of correlation between uCa and the markers of bone matrix ignificantly. The resorption, whether before or after therapy, also indicates the relain Figure 3 and tive inadequacy of uCa to correctly reflect bone destruction in Yo for D-Pyr, 77% patients with bone metastases. We found no evident relationship Serum calcium with the extent of bone metastatic involvement as evaluated by 11-' on day 7, but radiographs, but this should be further analysed in a larger series 1' on day 7 and of patients.
British Journal of Cancer (1997) When evaluating cross-linking amino acids of collagen (Pyr and D-Pyr) in patients with TIH, we observed that these markers of bone matrix resorption were relatively less increased than uCa and that they also decreased less after therapy (Body and Delmas, 1992) . The meaning of our observations was, however, unclear as uCa levels are influenced by the filtered load of calcium which is obviously increased in TIH and by the recovery of PTH secretion after bisphosphonate therapy . Nevertheless, Coleman et al have also observed in a series of 20 patients with breast cancer-induced osteolysis that the decrease in Pyr and D-Pyr after oral pamidronate therapy was lower than the fall in uCa (Coleman et al, 1992) . These findings could thus suggest a preferential removal of bone mineral rather than bone matrix during the process of malignant osteolysis and a similar preferential inhibitory activity of bisphosphonates (Body and Delmas, 1992; Coleman et al, 1992) . However, the present data do not support this hypothesis. Urinary calcium was thus less often and less markedly increased than markers of bone matrix destruction before therapy. After bisphosphonate, the fall in CrossLaps excretion was also more marked than the fall in uCa despite the fact that the increase in PTH secretion contributed to the latter. Moreover, our data also argue against the existence of a marked uncoupling between bone resorption and bone formation in patients with tumour-induced osteolysis (Body, 1992) . Although more sensitive markers of bone formation are needed to fully assess this hypothesis, bone resorption was relatively more increased than bone formation; but the correlations between markers of bone resorption and Alkaline Phosphatase levels were all statistically significant. The fact that these correlations were no longer present and that there were no significant changes in BGP or alkaline phosphatase levels after pamidronate therapy suggest that bisphosphonates can indeed uncouple bone turnover in a favourable direction. Bisphosphonates offer great promise for the treatment and the prevention of bone metastases. Optimal therapeutic schemes remain, however, to be determined and the sequential measurement of markers of bone matrix resorption should help in the selection of adequate therapeutic regimens.
